This is the first time that a clinically acceptable, CNS penetrant molecule has been shown to activate the Nrf2-ARE pathway in vivo and ameliorate disease measures in both mouse and patient fibroblast models of ALS. Here, NFE2L2 is linked to amyotrophic lateral sclerosis.